JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-8.6M

47M

Müük

-21M

699M

P/E

Sektori keskmine

50.083

37.003

Aktsiakasum

0.4

Dividenditootlus

0.28

Kasumimarginaal

6.675

Töötajad

11,000

EBITDA

-14M

181M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+15.19% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.28%

2.25%

Järgmine dividendimakse kuupäev

7. nov 2025

Järgmine aktsia dividendi kuupäev (ex-date)

16. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

584M

11B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

31%

69%

98 / 373 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. okt 2025, 23:28 UTC

Kuumad aktsiad

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29. okt 2025, 23:07 UTC

Tulu

Prudential PLC 3Q New Business Profit Up 13%

30. okt 2025, 00:00 UTC

Tulu

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30. okt 2025, 00:00 UTC

Tulu

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30. okt 2025, 00:00 UTC

Tulu

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29. okt 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29. okt 2025, 23:40 UTC

Tulu

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29. okt 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29. okt 2025, 23:25 UTC

Tulu

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29. okt 2025, 22:51 UTC

Tulu

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29. okt 2025, 22:45 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29. okt 2025, 22:41 UTC

Tulu

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29. okt 2025, 22:41 UTC

Tulu

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29. okt 2025, 22:09 UTC

Tulu

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29. okt 2025, 22:08 UTC

Market Talk
Tulu

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29. okt 2025, 21:58 UTC

Tulu

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29. okt 2025, 21:58 UTC

Tulu

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29. okt 2025, 21:57 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29. okt 2025, 21:54 UTC

Tulu

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29. okt 2025, 21:46 UTC

Tulu

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29. okt 2025, 21:43 UTC

Tulu

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29. okt 2025, 21:43 UTC

Tulu

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29. okt 2025, 21:42 UTC

Tulu

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29. okt 2025, 21:42 UTC

Tulu

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29. okt 2025, 21:41 UTC

Tulu

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29. okt 2025, 21:41 UTC

Tulu

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29. okt 2025, 21:41 UTC

Tulu

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29. okt 2025, 21:41 UTC

Tulu

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29. okt 2025, 21:40 UTC

Tulu

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29. okt 2025, 21:39 UTC

Tulu

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

15.19% tõus

12 kuu keskmine prognoos

Keskmine 111.1 USD  15.19%

Kõrge 125 USD

Madal 100 USD

Põhineb 11 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

8

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

98 / 373 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat